What are the most promising R&D efforts or recent developments in the space that are paving the way for extra-hepatic delivery?
The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.
On October 4, 2022 Bioprocess Online Live hosted a panel discussion digging into the scientific-, development-, and business-related advancements that will enable the RNA therapeutics industry to meet the needs of a broader array of patient populations.
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.